HIV-1 Variable Loop 2 and its Importance in HIV-1 Infection and Vaccine Development

被引:27
|
作者
Rao, Mangala [1 ]
Peachman, Kristina K. [1 ,3 ]
Kim, Jiae [1 ,3 ]
Gao, Guofen [2 ]
Alving, Carl R. [1 ]
Michael, Nelson L. [1 ]
Rao, Venigalla B. [2 ]
机构
[1] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA
[2] Catholic Univ Amer, Washington, DC 20064 USA
[3] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA
关键词
alpha 4 beta 7 integrin receptor; HIV-1; gp120; RV144; V2; loop; vaccine; HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTRALIZING ANTIBODY-RESPONSE; GP120 ENVELOPE GLYCOPROTEIN; T-CELL DEPLETION; SIMIAN IMMUNODEFICIENCY; MONOCLONAL-ANTIBODIES; EFFICACY TRIAL; V1/V2; REGION; DOUBLE-BLIND; INTEGRIN ALPHA(4)BETA(7);
D O I
10.2174/1570162X113116660064
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A vaccine that can prevent the transmission of HIV-1 at the site of exposure to the host is one of the best hopes to control the HIV-1 pandemic. The trimeric envelope spike consisting of heterodimers, gp120 and gp41, is essential for virus entry and thus has been a key target for HIV-1 vaccine development. However, it has been extremely difficult to identify the types of antibodies required to block the transmission of various HIV-1 strains and the immunogens that can elicit such antibodies due to the high genetic diversity of the HIV-1 envelope. The modest efficacy of the gp120 HIV-1 vaccine used in the RV144 Thai trial, including the studies on the immune correlates of protection, and the discovery of vaccine-induced immune responses to certain signature regions of the envelope have shown that the gp120 variable loop 2 (V2) is an important region. Since there is evidence that the V2 region interacts with the integrin 4 7 receptor of the host cell, and that this interaction might be important for virus capture, induction of antibodies against V2 loop could be postulated as one of the mechanisms to prevent the acquisition of HIV-1. Immunogens that can induce these antibodies should therefore be taken into consideration when designing HIV-1 vaccine formulations.
引用
收藏
页码:427 / 438
页数:12
相关论文
共 50 条
  • [1] Pneumococcal vaccine and HIV-1 infection
    Fedson, DS
    Watson, M
    LANCET, 2000, 356 (9237): : 1272 - 1272
  • [2] Diversity of Antibody Germline Gene and HIV-1 Infection: Implication for HIV-1 Vaccine
    Guan, Yongjun
    Yu, Lei
    Zhan, Ming
    Gallo, Robert C.
    Liu, Tongyun
    Sajadi, Mohammad
    DeVico, Anthony L.
    Lewis, George K.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 : 53 - 53
  • [3] HIV-1 diversity and vaccine development
    Nabel, G
    Makgoba, W
    Esparza, J
    SCIENCE, 2002, 296 (5577) : 2335 - 2335
  • [4] Role of TLRs in HIV-1 Infection and Potential of TLR Agonists in HIV-1 Vaccine Development and Treatment Strategies
    Rozman, Marija
    Zidovec-Lepej, Snjezana
    Jambrosic, Karlo
    Babic, Maja
    Drmic Hofman, Irena
    PATHOGENS, 2023, 12 (01):
  • [5] Challenges in the development of an HIV-1 vaccine
    Barouch, Dan H.
    NATURE, 2008, 455 (7213) : 613 - 619
  • [6] Progress in HIV-1 vaccine development
    Haynes, Barton F.
    McElrath, M. Juliana
    CURRENT OPINION IN HIV AND AIDS, 2013, 8 (04) : 326 - 332
  • [7] Advances in HIV-1 Vaccine Development
    Gao, Yong
    McKay, Paul E.
    Mann, Jamie E. S.
    VIRUSES-BASEL, 2018, 10 (04):
  • [8] Progress in HIV-1 vaccine development
    Haynes, Barton F.
    Moody, M. Anthony
    Alam, Munir
    Bonsignori, Mattia
    Verkoczy, Laurent
    Ferrari, Guido
    Gao, Feng
    Tomaras, Georgia D.
    Liao, Hua-Xin
    Kelsoe, Garnett
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (01) : 3 - 10
  • [9] Challenges in the development of an HIV-1 vaccine
    Dan H. Barouch
    Nature, 2008, 455 : 613 - 619
  • [10] Progress in the development of an HIV-1 vaccine
    Letvin, NL
    SCIENCE, 1998, 280 (5371) : 1875 - 1880